Ztalmy (ganaxolone oral suspension) — Medica

Initial criteria

• Patient is age ≥ 2 years
• Patient has a molecularly confirmed pathogenic or likely pathogenic variant in the CDKL5 gene
• Patient has tried and/or is concomitantly receiving at least two other antiseizure medications (e.g., clobazam, Epidiolex [cannabidiol oral solution], lacosamide, lamotrigine, levetiracetam, phenobarbital, rufinamide, topiramate, valproate, vigabatrin, zonisamide)
• Medication is prescribed by or in consultation with a neurologist

Approval duration

1 year